John R. Desjarlais
Net Worth

Last updated:

What is John R. Desjarlais net worth?

The estimated net worth of Dr. John R. Desjarlais is at least $12,994,791 as of 12 Nov 2024. He owns shares worth $1,548,805 as insider, has earned $3,790,826 from insider trading and has received compensation worth at least $7,655,160 in Xencor, Inc..

What is the salary of John R. Desjarlais?

Dr. John R. Desjarlais salary is $637,930 per year as Senior Vice President of Research & Chief Scientific Officer in Xencor, Inc..

How old is John R. Desjarlais?

Dr. John R. Desjarlais is 61 years old, born in 1964.

What stocks does John R. Desjarlais currently own?

As insider, Dr. John R. Desjarlais owns shares in one company:

Company Title Shares Price per share Total value
Xencor, Inc. (XNCR) Senior Vice President of Research & Chief Scientific Officer 200,104 $7.74 $1,548,805

What does Xencor, Inc. do?

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR logo
XNCR
Xencor, Inc.
$7.74

John R. Desjarlais insider trading

Xencor, Inc.

Dr. John R. Desjarlais has made 21 insider trades between 2013-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 117,741 units of XNCR stock on 5 Dec 2016. As of 12 Nov 2024 he still owns at least 200,104 units of XNCR stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 12,774 $15.69 $200,424
Option
Stock Option (Right to Buy) 12,774 $15.69 $200,424
Option
Stock Option (Right to Buy) 68,684 $15.69 $1,077,652
Sale
Common Stock 68,684 $23.48 $1,612,632
Option
Common Stock 68,684 $15.69 $1,077,652
Option
Common Stock 7,785 $10.73 $83,533
Option
Stock Option (Right to Buy) 7,785 $10.73 $83,533
Sale
Common Stock 36,329 $18.32 $665,511
Option
Stock Option (Right to Buy) 42,215 $10.73 $452,967
Option
Common Stock 42,215 $10.73 $452,967
Sale
Common Stock 1,280 $23.5 $30,083
Sale
Common Stock 6,629 $23.43 $155,311
Option
Common Stock 11,943 $11.05 $131,970
Option
Stock Option (Right to Buy) 11,943 $11.05 $131,970
Option
Stock Option (Right to Buy) 68,057 $11.05 $752,030
Sale
Common Stock 54,108 $19.38 $1,048,721
Option
Common Stock 68,057 $11.05 $752,030
Sale
Common Stock 1,230 $29.88 $36,751
Sale
Common Stock 4,195 $31.42 $131,790
Sale
Common Stock 1,232 $31.54 $38,855
Sale
Common Stock 1,172 $29.13 $34,140
Sale
Common Stock 1,240 $29.87 $37,033
Sale
Common Stock 1,165 N/A N/A
Option
Stock Option (right to buy) 27,522 N/A N/A
Option
Common Stock 27,522 N/A N/A
Sale
Common Stock 35,000 N/A N/A
Sale
Common Stock 14,867 N/A N/A
Option
Stock Option (right to buy) 35,000 N/A N/A
Option
Common Stock 35,000 N/A N/A
Sale
Common Stock 20,133 N/A N/A
Sale
Common Stock 13,755 N/A N/A
Option
Stock Option (right to buy) 117,741 N/A N/A
Sale
Common Stock 45,000 N/A N/A
Option
Common Stock 117,741 N/A N/A
Sale
Common Stock 16,294 N/A N/A
Sale
Common Stock 5,905 N/A N/A
Option
Common Stock 13,776 N/A N/A
Sale
Common Stock 5,270 N/A N/A
Option
Stock Option (right to buy) 6,888 N/A N/A
Sale
Common Stock 22,890 N/A N/A
Option
Stock Option (right to buy) 28,653 N/A N/A
Option
Common Stock 28,653 N/A N/A
Option
Stock Option (right to buy) 1,733 N/A N/A
Option
Common Stock 1,733 N/A N/A
Option
Stock Option (right to buy) 1,100 N/A N/A
Sale
Common Stock 1,100 N/A N/A
Option
Common Stock 1,100 N/A N/A
Option
Common Stock 26,294 N/A N/A
Option
Stock Option (Right to Buy) 23,069 N/A N/A
Option
Stock Option (Right to Buy) 207 N/A N/A
Option
Common Stock 243 N/A N/A

Xencor key executives

Xencor, Inc. executives and other stock owners filed with the SEC: